Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Paclitaxel protein-bound"'
Publikováno v:
European Journal of Ophthalmology. 32:602-611
Purpose: To investigate ophthalmic side effects of taxanes and compare side effect frequency, requirement for cessation of taxane therapy, visual acuity outcome, and concurrent systemic effects between paclitaxel and docetaxel. Methods: Patients taki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f30b9e33e77788c0e0f2d88161f2b846
https://doi.org/10.1177/1120672120969045
https://doi.org/10.1177/1120672120969045
Autor:
Laura W. Goff, Marc T. Roth
Publikováno v:
JAMA oncology. 5(6)
IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::588383b53d31fa9900d884906eb40112
https://pubmed.ncbi.nlm.nih.gov/30998813
https://pubmed.ncbi.nlm.nih.gov/30998813
Autor:
D. D. Von Hoff, Gayle S. Jameson
Publikováno v:
European Journal of Cancer. 138:S55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77e93b5304fad2db82c52f6f766d365a
https://doi.org/10.1016/s0959-8049(20)31224-7
https://doi.org/10.1016/s0959-8049(20)31224-7
Autor:
Ronald L. Korn, Courtney Snyder, Sunil Sharma, Erkut Borazanci, Kevin Gosselin, Gayle S. Jameson, Rachel Wyman, Syed Rahmanuddin, Frank Tsai, Albert Amini, Amar Thosani, Carol Guarnieri, Daniel D. Von Hoff, Michael S. Gordon, Steven Sckolnik, Sharon Salontai, Susan Haag
Publikováno v:
Journal of Clinical Oncology. 38:4631-4631
4631 Background: Localized PDAC management has recently evolved. Due to concerns over micro metastases at diagnosis the use of neoadjuvant chemotherapy for PDAC has become more common. Typical therapies involve the use of multiagent systemic chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9d2980687b2428b3443ec589f5838bb
https://doi.org/10.1200/jco.2020.38.15_suppl.4631
https://doi.org/10.1200/jco.2020.38.15_suppl.4631
Publikováno v:
Japanese journal of clinical oncology. 48(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5acad2ddf8d6a06c58a0d5aa1ec8225b
https://pubmed.ncbi.nlm.nih.gov/29901731
https://pubmed.ncbi.nlm.nih.gov/29901731
Autor:
Chengping Hu, Z. Wang, Lin Zhang, L. Paz-Ares, Ying Cheng, Hongjun Gao, Jiwei Liu, Y. Tian, H. Wang, Jiaojiao Zhou, D. Wang, J. Ge, Juncheng Hu, H. Zhang, H. Sun, L. Wu, Bilal Piperdi, L. Cao
Publikováno v:
Annals of Oncology. 30:ix201-ix202
Background The primary analysis of OS and PFS in the randomized KEYNOTE-407 study, at median follow-up of 7.8 months, showed that pembro + carboplatin and paclitaxel/nab-paclitaxel (chemo) significantly improved OS (HR, 0.64 [95% CI, 0.49–0.85]; P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a5d353bb137398bbdfe840f0cce1350
https://doi.org/10.1093/annonc/mdz446.019
https://doi.org/10.1093/annonc/mdz446.019
Autor:
Balazs Medgyasszay, X. Deng, Irfan Cicin, Andrew G. Robinson, Barbara Hermes, Julien Mazieres, Ali Tafreshi, Ying Cheng, Sung Sook Lee, J. Rodriguez Cid, Luis Paz-Ares, Tuba Bas, Rodryg Ramlau, H. Soto Parra, V. Vladimirov, David Vicente, Isamu Okamoto, Balazs Halmos, B. Beatrix, Bilal Piperdi
Publikováno v:
Annals of Oncology. 30:v918-v919
Background In the randomized KEYNOTE-407 study (NCT02775435), pembro + carboplatin and paclitaxel/nab-paclitaxel (chemo) significantly improved OS, PFS, and ORR compared with placebo + chemo in patients (pts) with previously untreated metastatic squa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c6bb39bca9cd29a1220201b9bb06371
https://doi.org/10.1093/annonc/mdz394.080
https://doi.org/10.1093/annonc/mdz394.080
Autor:
Peter Sinn, Katja Steiger, Annette Lebeau, Daniel-Christoph Wagner, Johannes Ammann, Aurelia Noske, Wilko Weichert, Carsten Denkert, Stefanie Hieke-Schulz, Marion Kiechle, Wilfried Roth, Gustavo B. Baretton, Hans Kreipe
Publikováno v:
Annals of Oncology. 30:v130-v131
Background Atezolizumab (an anti–PD-L1 antibody) has shown clinical activity alone or in combination with nab-paclitaxel in patients (pts) with first-line metastatic TNBC who have PD-L1 expression on their tumour-infiltrating immune cells (IC). We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e7fe23b17f7adfdfe2cb588d97fd159
https://doi.org/10.1093/annonc/mdz242.054
https://doi.org/10.1093/annonc/mdz242.054
Autor:
Satoshi Otsu, Yasushi Ide, Taiga Otsuka, Masaru Fukahori, Junichi Nakazawa, Yujiro Ueda, Norio Ureshino, Taro Shibuki, Kenta Nio, Mototsugu Shimokawa, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Shiho Arima, Kenji Mitsugi, Tsuyoshi Shirakawa, Futa Koga
Publikováno v:
Annals of Oncology. 30:iv17-iv18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20ce5732f1f913031c3acdfe6a3e2f5d
https://doi.org/10.1093/annonc/mdz155.064
https://doi.org/10.1093/annonc/mdz155.064
Autor:
Giuseppe Tisone, G. Del Vecchio Blanco, Giuseppe Palmieri, Alessandro Anselmo, M. Benassi, Cristina Morelli, Vincenzo Formica, Mario Roselli, A. Nardecchia, Jessica Lucchetti, Renato Argirò
Publikováno v:
Annals of Oncology. 30:iv57-iv58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ac61f2accd95cfe5dea5fe8bd0f331
https://doi.org/10.1093/annonc/mdz155.210
https://doi.org/10.1093/annonc/mdz155.210